

Sangeetha Reddy, MD, MSci
sangeetha.reddy@utsouthwestern.edu
617-216-0167

ACADEMIC EMPLOYMENT

2019-Current **University of Texas Southwestern Medical Center**, Dallas, TX
Assistant Professor, Department of Medicine, Division of Hematology-Oncology

2017-2018 **University of Texas MD Anderson Cancer Center**, Houston, TX
Research Instructor, Department of Breast Medical Oncology

2013-2014 **McGaw Medical Center of Northwestern University**, Chicago, IL
Chief Medical Resident, Clinical Instructor, Department of Internal Medicine

EDUCATION AND POSTGRADUATE TRAINING

2014-2017 **The University of Texas MD Anderson Cancer Center**, Houston, TX
Fellowship in Medical Hematology-Oncology
NIH T32 Fellow

2012-2014 **Northwestern University**, Chicago, IL
Master of Science in Clinical Investigation

2010-2013 **McGaw Medical Center of Northwestern University**, Chicago, IL
Internship and Residency in Internal Medicine

2006-2010 **UCLA David Geffen School of Medicine**, Los Angeles, CA
Doctor of Medicine
Alpha Omega Alpha Medical Honor Society

2002-2006 **Harvard University**, Cambridge, MA
Bachelor of Arts in Biochemical Sciences
Graduated *cum laude*

CREDENTIALS

Board Certification

American Board of Internal Medicine, 341399, 2013-2023
Medical Oncology, 2017-2027

Licensure

Texas Medical Board, TX, Q0547, 7/2014-8/2019

HONORS AND AWARDS

2019 Disease Oriented Clinical Scholar Award
2019 Cancer Prevention and Research Institute of Texas Recruitment Award
2018 Society for Immunotherapy of Cancer Young Investigator Award

2018	Society for Melanoma Research Travel Award
2018	Selection to participate in 2 nd Annual Society for Immunotherapy of Cancer Sparkathon
2018	1 st Place Immuno-Oncology Young Investigator Forum, Clinical Faculty
2017	AACR Scholar-in-Training Award
2017	Presidential Travel Award for SITC Annual Meeting (given to top 4 abstracts)
2017	Conquer Cancer Foundation Merit Award
2016	Zeta Tau Alpha Houston Alumnae Association Fellowship in IBC Research
2016	ASCO/BCRF Young Investigator Award
2016	ASCO/AACR Methods in Clinical Cancer Research Workshop
2016	Finalist Trainee Excellence, State of the Science Survivorship Symposium
2015-2017	NIH T32 Research Fellow
2015	Miami Breast Cancer Conference Sponsored Fellow
2013	Finalist Landsberg Research Day Competition, Northwestern University
2011	Northwestern Memorial Hospital Goldberg Trust Award
2011	Second Place Research Poster, ACP Northern Illinois Conference
2013-2014	Excellence in Teaching Awards, Northwestern Feinberg School of Medicine
2010	Alpha Omega Alpha Society Medical Honor Society
2009	June and Sherman M. Mellinkoff Medical Alumni Scholarship
2009	Best Medical Student Clinical Vignette, ACP Southern California Conference
2007	UCLA Internal Medicine Chief's Fellowship
2005	John Harvard Scholarship, Harvard University
2005	Howard Hughes Research Summer Grant, Harvard University

FUNDING

Grants

1. Disease Oriented Clinical Scholar Award, PI: Sangeetha Reddy, 02/2019-02/2022, \$1,000,000
2. Cancer Prevention Research Institute Award Recruitment of First-Time, Tenure-Track Faculty Members Award, PI: Sangeetha Reddy, 02/2019-02/2024, \$2,000,000
3. ASCO Young Investigator Award, PI: Sangeetha Reddy, 7/2016-12/2017, \$50,000
4. Supplemental Funds to ASCO Young Investigator Award, PI: Sangeetha Reddy, 07/2016-12/2017, \$10,000

PUBLICATIONS

Articles in Peer Reviewed Journals

1. **Reddy SM**, Reuben AR, Barua S, Zhang S, Jiang H, Tetzlaff MT, Gopalakrishnan V, Reuben J, Wang L, Tsujikawa T, Wani K, He Y, Rao A, Villareal L, Wood A, Woodward W, Ueno NT, Krishnamurthy S, Mittendorf EM, Wargo J. Mast cell infiltration correlates with poor response to neoadjuvant chemotherapy in inflammatory breast cancer. *Cancer Immunol Res*. 2019 May 1.
2. Amaria RN*, **Reddy SM*** (*co-first authorship), Tawbi H, Davies M, Ross M, Glitza I, Cormier J, Lewis CM, Hwu WJ, Hanna EY, [...] Tetzlaff MT, Wargo J. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nature Medicine*. 2018 Nov;24(11):1649-1654.
3. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, De Boer, CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani A, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane J, Hammon MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, **Reddy SM**, [...] Hacohen N. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. *Cell*. 2018 Nov 1;175(4):998-1013.e20.
4. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R,

- Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, **Reddy S**, [...] Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomized, phase 2 trial. *Lancet Oncol*. 2018 Feb;19(2):181-193
5. Gopalakrishnan V, Spencer C, Nezi L, Reuben A, Andrews M, Karpinets T, Prieto P, Vicente D, Hoffman K, Wei S, Cogdill A, Zhao L, Hudgens C, Hutchinson D, Manzo T, Petaccia de Macedo M, Cotechini R, Kumar T, Chen WS, **Reddy S**, [...] Wargo J. Gut microbiome impacts response to PD-1 immunotherapy in melanoma patients. *Science*. 2018 Jan 5;359(6371):97-103.
 6. **Reddy SM**, Barcenas C, Sinha A, Hsu L, Moulder S, Tripathy D, Hortobagyi G, Valero V. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease-free at 5 years and relationship with low hormone receptor positivity. *British Journal of Cancer*. 2018 Jan;118(1):17-23.
 7. Gall V, Philips A, Qiao N, Clise-Dwyer K, Perakis A, Zhang M, Clifton G, Sukhumalchandra P, Ma Q, **Reddy SM**, Yu D, Molldrem J, Peoples G, Alatrash G, Mittendorf E. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. *Cancer Research*. 2017 Oct 1;77(19):5374-5383.
 8. Shaitelman SF, Stauder MC, Allen P, **Reddy S**, Lakoski S, Atkinson B, Reddy J, Amaya D, Guerra W, Ueno N, Caudle A, Tereffe W, Woodward WA. Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. *J Cancer* 2017; 8(11):2026-2032.
 9. Szczepaniak R, Gopalakrishnan V, **Reddy SM**, Zhang X, Reuben A, Wargo JA. Interaction of molecular alterations with immune response in melanoma. *Cancer*. 2017 Jun 1;123(S11):2130-2142.
 10. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, **Reddy SM**, [...] Wargo J. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. *NPJ Genomic Medicine*. 2017 April 7: 2(10).
 11. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, **Reddy SM**, [...] Wargo J. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. *Sci Transl Med*. 2017 Mar 1;9(379).
 12. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, **Reddy SM**, [...] Wargo J. Analysis of immune signatures in longitudinal tumor samples yields insights into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. *Cancer Discov*. 2016 Aug;6(8):827-37.
 13. Wargo JA*, **Reddy SM*** (*co-first authorship), Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. *Current Opinion in Immunology*. 2016 Aug;41:23-31.
 14. **Reddy SM**, Reuben A, Wargo JA. Influences of BRAF inhibitors on the immune microenvironment and the rationale for combined molecular and immune targeted therapy. *Current Oncology Reports*. 2016 Jul;18(7):42.
 15. **Reddy SM**, Vergo MT, Paice JA, Kwon N, Helenowski IB, Benson AB, Mulcahy MF, Nimeiri H, Harden RN. Quantitative sensory testing at baseline and during cycle 1 oxaliplatin infusion detects subclinical peripheral neuropathy and predicts clinically overt chronic neuropathy in gastrointestinal malignancies. *Clinical Colorectal Cancer*. 2016 Mar;15(1):37-46.
 16. **Reddy SM**, Gallick G, Eng C. Phase II Study of Saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. *Invest New Drugs*. 2015, 33(4): 977-984.
 17. **Reddy SM**, Sadim M, Helenowski IB, Li J, Yi N, Kaklamani VG. Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. *British Journal of Cancer*. 2013, 109: 872-881.
 18. **Reddy S**, Raffin M, Kaklamani V. Targeting angiogenesis in metastatic breast cancer. *The Oncologist*. 2012, 17(8): 1014-1026.
 19. **Reddy SM**, Vergo M, Benson AB. Prognostic and predictive markers in colorectal cancer. *Current Colorectal Cancer Reports*. 2011, 7(4).
 20. **Reddy SM**, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant cytomegalovirus infection and protracted immunodeficiency. *Bone Marrow Transplant*. 2010, 45: 979-984.

Pending

1. Helmink BH*, **Reddy SM*** (*co-first authorship), Gao J, Zhang S, Sade-Feldman M, Yizhak K, Blando J, Han G, Zhao H, Tawbi H, Amaria RN, Davies MA, Hwu P, Lee JE, Gershenwald J, Burton EM, Haydu L, Lazar AJ, Hudgens CW, Cogdill A, Keung E, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Butterfield, Allison J, Tetzlaff MT, Wu C, Hacohen N, Sharma P, Wang L, Wargo JA. B-cells and tertiary lymphoid structures predict immune checkpoint blockade response. Under review at Nature.

CONFERENCES AND SYMPOSIA

Presentations at National or International Conferences

Oral Presentations

1. **Reddy SM**, Helmink BH, Gao J, Zhang S, Sade-Feldman M, Yizhak K, Blando J, Han G, Zhao H, Tawbi H, Amaria RN, Davies MA, Hwu P, [...] Wargo J. Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors. AACR Annual Meeting. March, 2019. Atlanta, GA.
2. **Reddy SM**, Helmink BH, Gao J, Zhang S, Sade-Feldman M, Yizhak K, Blando J, Han G, Zhao H, Tawbi H, Amaria RN, Davies MA, Hwu P, [...] Wargo J. B-cells and tertiary lymphoid structures (TLS) predict response to immune checkpoint blockade (ICB). Society for Immunotherapy of Cancer Annual meeting. November, 2018. Washington DC, MD.
3. **Reddy SM**, Amaria RN, Spencer CN, Tetzlaff M, Reuben A, Andrews M, [...] Wargo J. Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings. Society for Immunotherapy of Cancer Annual Meeting. Presidential Travel Award and oral presentation (awarded to top 4 abstracts). November, 2017. National Harbor, MD.
4. **Reddy SM**, Wargo JA, Reuben A, Tetzlaff MT, Roszik J, Reuben JM, Woodward W, Ueno NT, Krishnamurthy S, Mittendorf EA. Immune and Molecular Determinants of Response to Neoadjuvant Chemotherapy in Inflammatory Breast Cancer. J Clin Oncol 35, 2017 (suppl; abstr 11501). American Society of Clinical Oncology Annual Meeting. June, 2017. Chicago, IL. Awarded Conquer Cancer Foundation Merit Award.
5. **Reddy SM**, Krishnamurthy S, Reuben A, Reuben JM, Woodward W, Ueno NT, Wargo JA, Mittendorf EA. Immune Characterization of Inflammatory Breast Cancer and Correlation to Pathological Complete Response. Immuno-oncology Young Investigator's Forum. April, 2017. Houston, TX.

Poster Presentations

1. Alexander A, Marx AN, **Reddy SM**, Reuben JM, Le-Petross HT, Lane D, Huang M, Krishnamurthy S, Gong Y, Gombos D, Patel N, Tung C, Allen RC, Kandi T, Wu J, Liu S, Patel AB, Futreal A, Wistuba I, Layman R, Valero V, Ueno NT, Tripathy D, Lim B. A phase II study of triple combination of atezolizumab, cobimetinib and eribulin (ACE) for patients with recurrent/metastatic inflammatory breast cancer (IBC). Accepted for poster presentation at San Antonio Breast Cancer Symposium. December, 2018. San Antonio, TX.
2. **Reddy SM**, Reuben A, Barua S, Jiang H, Tetzlaff MT, Reuben JM, Wang L, Tsujikawa T, Roszik J, Rao A, Villareal L, Wood A, Woodward W, Ueno NT, Wargo J, Krishnamurthy S, Mittendorf EA. Lymphoid and myeloid cell characterization of inflammatory breast cancer tumor microenvironment and correlation to pathological complete response. San Antonio Breast Cancer Symposium. December, 2017. San Antonio, TX.

3. **Reddy SM**, Wargo JA, Reuben A, Reuben J, Woodward W, Ueno N, Mittendorf EA, Krishnamurthy S. Immune Characterization of Inflammatory Breast Cancer and Correlation to Pathological Complete Response. San Antonio Breast Cancer Symposium. December, 2016. San Antonio, TX.
4. **Reddy SM**, Sinha AK, Hsu L, Barcenas CH, Valero V. Recurrence and survival outcomes of triple-negative breast cancer survivors disease-free at 5-years and relationship to low hormone receptor positivity (1-9% versus <1%). J Clin Oncol 34, 2016 (suppl; abstr 1077). American Society of Clinical Oncology Annual Meeting. June, 2016. Chicago, IL.
5. **Reddy SM**, Sinha A, Masood PS, Barcenas C, Valero V. Recurrence and survival outcomes of triple negative breast cancer survivors and characterization of late events in the MD Anderson experience. San Antonio Breast Cancer Symposium. December, 2015. San Antonio, TX.
6. **Reddy SM**, Kwon N, Nimeiri HS, Mulcahy MF, Harden RN, Benson AB, Paice JA, Vergo MT. Using quantitative sensory testing as an early predictor of chronic oxaliplatin neuropathy in gastrointestinal cancer patients. J Clin Oncol 31, 2013 (suppl; abstr 3540). American Society of Clinical Oncology Annual Meeting. June, 2013. Chicago, IL.
7. **Reddy SM**, Sadim M, Helenowski IB, Li J, Yi N, Kaklamani VG. Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. J Clin Oncol 30 suppl 1561. American Society of Clinical Oncology Annual Meeting. June, 2012. Chicago, IL.
8. **Reddy S**, Kwon N, Nimeiri HS, Mulcahy MF, Harden RN, Benson AB, Paice JA, Vergo MT. Early thermal quantitative sensory testing to measure acute oxaliplatin neurotoxicity and predict chronic neuropathy in gastrointestinal malignancies. suppl 425. American Society of Clinical Oncology Gastrointestinal Cancer Symposium. January, 2012. San Francisco, CA.

State or Local Conferences

Oral Presentations

1. **Reddy SM**, Sinha A, Masood PS, Barcenas C, Valero V. Recurrence and survival outcomes of triple negative breast cancer survivors and predictors of late events. Fourth State of the Science Survivorship Research Symposium. January, 2016. Houston, TX. Awarded 2nd place trainee research award.

Poster Presentations

1. **Reddy SM**, Sadim M, Helenowski IB, Li J, Yi N, Kaklamani VG. Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. Landsberg Research Day. April, 2013. Chicago, IL. Awarded finalist for Women's Health Clinical Research.
2. **Reddy S**, Sadim M, Kaklamani V. Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. Regional ACP conference. November, 2011. Chicago, IL. Awarded 2nd place research poster.
3. **Reddy SM**, Winston DJ, Territo MC, Schiller GJ. Cytomegalovirus central nervous system disease after hematopoietic stem cell transplantation. UCLA Medicine Research Day. October, 2009. Los Angeles, CA. Awarded third place in Clinical and Health Services Research, Trainee Category.
4. **Reddy SM**, Hines J, Farrell J, Reber H, King J, Garon E. A presurgical, randomized clinical trial of genistein in resectable pancreatic adenocarcinoma: a novel way of studying pancreatic cancer. UCLA Medicine Research Day. October, 2009. Los Angeles, CA.
5. **Reddy SM**, Napolitano JD. From 'black & white' to red all over - how a straightforward case of streptococcal pharyngitis evolved into guttate psoriasis. Regional ACP Conference. October, 2009. Indian Wells, CA. Awarded best medical student vignette.

PROFESSIONAL SOCIETY MEMBERSHIPS

Society for Immunotherapy of Cancer, 2017-Current.
American Society of Clinical Oncology, 2012-Current
American Association for Cancer Research, 2016-Current
Alpha Omega Alpha Medical Honor Society, 2010-Current